.
The approval is for emergency situation use only in the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (severe breathing distress syndrome) clients due to COVID-19
Biopharmaceuticals firm Biocon has received Drugs Controller General of India (DCGI) approval for usage of its repurposed psoriasis drug Itolizumab injection 25 mg/5mL option in the treatment of COVID-19 clients.
The approval is for emergency situation use only in the treatment of cytokine release syndrome (CRS) in moderate to extreme ARDS (intense breathing distress syndrome) patients due to COVID-19, Biocon stated.
Also read
